Bioasis Technologies Inc. (BIOAF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | - CAD | -100.0% |
| 2022 | 170.99 Thousand CAD | 106.52% |
| 2021 | -2.62 Million CAD | -714.07% |
| 2020 | 427.18 Thousand CAD | 131.41% |
| 2019 | -1.36 Million CAD | -100.6% |
| 2018 | -677.97 Thousand CAD | -22.31% |
| 2017 | -554.28 Thousand CAD | 28.27% |
| 2016 | -772.74 Thousand CAD | 42.28% |
| 2015 | -1.33 Million CAD | -22.58% |
| 2014 | -1.09 Million CAD | 35.58% |
| 2013 | -1.69 Million CAD | -61.9% |
| 2012 | -1.04 Million CAD | 29.64% |
| 2011 | -1.48 Million CAD | 12.11% |
| 2010 | -1.69 Million CAD | -93.0% |
| 2009 | -877.33 Thousand CAD | -68602.43% |
| 2008 | -1277.00 CAD | 98.58% |
| 2007 | -90 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - CAD | 0.0% |
| 2024 Q2 | - CAD | 0.0% |
| 2023 Q2 | 1.43 Million CAD | 42.35% |
| 2023 Q4 | - CAD | -100.0% |
| 2023 Q1 | 1 Million CAD | 489.71% |
| 2023 Q3 | 2.05 Million CAD | 43.31% |
| 2023 FY | - CAD | -100.0% |
| 2022 Q3 | -572.63 Thousand CAD | 67.29% |
| 2022 FY | 170.99 Thousand CAD | 106.52% |
| 2022 Q1 | -1.76 Million CAD | 32.7% |
| 2022 Q2 | -1.75 Million CAD | 0.84% |
| 2022 Q4 | 170.99 Thousand CAD | 129.86% |
| 2021 Q4 | -2.62 Million CAD | -2.17% |
| 2021 Q1 | 358.18 Thousand CAD | -16.15% |
| 2021 Q3 | -2.56 Million CAD | -40.59% |
| 2021 Q2 | -1.82 Million CAD | -609.84% |
| 2021 FY | -2.62 Million CAD | -714.07% |
| 2020 Q3 | -84.24 Thousand CAD | 86.7% |
| 2020 FY | 427.18 Thousand CAD | 131.41% |
| 2020 Q4 | 427.18 Thousand CAD | 607.06% |
| 2020 Q2 | -633.53 Thousand CAD | 60.42% |
| 2020 Q1 | -1.6 Million CAD | -17.68% |
| 2019 FY | -1.36 Million CAD | -100.6% |
| 2019 Q4 | -1.36 Million CAD | 25.12% |
| 2019 Q3 | -1.81 Million CAD | 6.35% |
| 2019 Q2 | -1.93 Million CAD | -47.84% |
| 2019 Q1 | -1.31 Million CAD | -93.5% |
| 2018 FY | -677.97 Thousand CAD | -22.31% |
| 2018 Q4 | -677.97 Thousand CAD | 65.12% |
| 2018 Q2 | -2.53 Million CAD | 30.81% |
| 2018 Q1 | -3.66 Million CAD | -561.54% |
| 2018 Q3 | -1.94 Million CAD | 23.38% |
| 2017 Q3 | -856.53 Thousand CAD | 17.14% |
| 2017 Q2 | -1.03 Million CAD | 24.32% |
| 2017 Q1 | -1.36 Million CAD | -76.74% |
| 2017 FY | -554.28 Thousand CAD | 28.27% |
| 2017 Q4 | -554.28 Thousand CAD | 35.29% |
| 2016 Q3 | -125.96 Thousand CAD | -103.28% |
| 2016 Q4 | -772.74 Thousand CAD | -513.44% |
| 2016 Q2 | -61.96 Thousand CAD | 94.37% |
| 2016 Q1 | -1.1 Million CAD | 17.78% |
| 2016 FY | -772.74 Thousand CAD | 42.28% |
| 2015 Q3 | -2.09 Million CAD | -5.8% |
| 2015 Q1 | -1.09 Million CAD | -0.01% |
| 2015 Q2 | -1.98 Million CAD | -81.3% |
| 2015 FY | -1.33 Million CAD | -22.58% |
| 2015 Q4 | -1.33 Million CAD | 36.1% |
| 2014 Q3 | -1.44 Million CAD | -19.08% |
| 2014 Q1 | -3.19 Million CAD | -88.53% |
| 2014 FY | -1.09 Million CAD | 35.58% |
| 2014 Q4 | -1.09 Million CAD | 24.23% |
| 2014 Q2 | -1.21 Million CAD | 62.13% |
| 2013 FY | -1.69 Million CAD | -61.9% |
| 2013 Q4 | -1.69 Million CAD | 31.44% |
| 2013 Q3 | -2.47 Million CAD | -174.34% |
| 2013 Q1 | -969.28 Thousand CAD | 7.44% |
| 2013 Q2 | -901.4 Thousand CAD | 7.0% |
| 2012 FY | -1.04 Million CAD | 29.64% |
| 2012 Q4 | -1.04 Million CAD | 26.3% |
| 2012 Q3 | -1.42 Million CAD | -98.54% |
| 2012 Q2 | -715.66 Thousand CAD | 31.0% |
| 2012 Q1 | -1.03 Million CAD | 30.31% |
| 2011 Q1 | -1.38 Million CAD | 17.95% |
| 2011 Q3 | -1.66 Million CAD | 0.0% |
| 2011 Q4 | -1.48 Million CAD | 10.37% |
| 2011 FY | -1.48 Million CAD | 12.11% |
| 2010 FY | -1.69 Million CAD | -93.0% |
| 2010 Q4 | -1.69 Million CAD | 17.25% |
| 2010 Q3 | -2.04 Million CAD | 7.83% |
| 2010 Q1 | -2.47 Million CAD | -181.83% |
| 2010 Q2 | -2.22 Million CAD | 10.21% |
| 2009 Q2 | -982.47 Thousand CAD | 9.15% |
| 2009 Q4 | -877.33 Thousand CAD | -2.17% |
| 2009 Q3 | -858.69 Thousand CAD | 12.6% |
| 2009 FY | -877.33 Thousand CAD | -68602.43% |
| 2009 Q1 | -1.08 Million CAD | -84588.33% |
| 2008 Q2 | -566.14 Thousand CAD | 0.0% |
| 2008 Q3 | -488.55 Thousand CAD | 13.7% |
| 2008 Q4 | -1277.00 CAD | 99.74% |
| 2008 FY | -1277.00 CAD | 98.58% |
| 2007 FY | -90 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 100.0% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 100.0% |
| Mesoblast Limited | 55.85 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 100.0% |
| Genus plc | 190.6 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 100.0% |
| Marizyme, Inc. | 18.56 Million USD | 100.0% |
| ContraFect Corporation | -6.02 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 100.0% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 90.04 USD | 100.0% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 100.0% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 100.0% |
| EV Biologics, Inc. | 1.36 Million USD | 100.0% |
| Q BioMed Inc. | 4.06 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 100.0% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 100.0% |
| Biomind Labs Inc. | 711.4 Thousand USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Pharming Group N.V. | 109.8 Million USD | 100.0% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 100.0% |
| Skye Bioscience, Inc. | -5.72 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 100.0% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 100.0% |
| IMV Inc. | 7.67 Million USD | 100.0% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 100.0% |
| GB Sciences, Inc. | 1.74 Million USD | 100.0% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 100.0% |
| HST Global, Inc. | 96.79 Thousand USD | 100.0% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Halberd Corporation | 144.72 Thousand USD | 100.0% |
| Enzolytics Inc. | 981.65 Thousand USD | 100.0% |
| Resverlogix Corp. | 6.45 Million USD | 100.0% |
| Affymax, Inc. | -5.59 Million USD | 100.0% |
| SYBLEU INC | 473.71 Thousand USD | 100.0% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 100.0% |
| argenx SE | -2.02 Billion USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 100.0% |
| AVAX Technologies, Inc. | -5.9 Million USD | 100.0% |
| Zenith Capital Corp. | 10.06 Thousand USD | 100.0% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Helix BioMedix, Inc. | -2.57 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 100.0% |
| BioStem Technologies, Inc. | 4.47 Million USD | 100.0% |
| ONE Bio Corp. | 9.04 Million USD | 100.0% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 100.0% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 100.0% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 100.0% |
| Agentix Corp. | 37.63 Thousand USD | 100.0% |
| LadRx Corporation | -2.03 Million USD | 100.0% |
| Cell Source, Inc. | 9.23 Million USD | 100.0% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.17 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 100.0% |
| Itoco Inc. | 228.3 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 100.0% |
| Kadimastem Ltd | -253.1 Thousand USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 100.0% |
| CytoDyn Inc. | 20.26 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 100.0% |
| Mobile Lads Corp. | 484.23 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 100.0% |
| Qrons Inc. | 351.42 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 305 Thousand USD | 100.0% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 100.0% |
| International Stem Cell Corporation | 2.59 Million USD | 100.0% |
| Bioxytran, Inc. | 1.89 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 2.18 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 3.43 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 772.6 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 100.0% |
| Neutra Corp. | 52.18 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 100.0% |
| PureTech Health plc | -167.19 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 100.0% |
| IXICO plc | -4.44 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 100.0% |
| CSL Limited | 10.52 Billion USD | 100.0% |
| Cellectis S.A. | -43.81 Million USD | 100.0% |